Mechanism of Action
Lectin-Like Viral Neutralization
Theta-defensins act as lectins, binding to glycosylated proteins on the surface of enveloped viruses including HIV-1, herpes simplex virus, and influenza. By crosslinking viral envelope glycoproteins, they prevent fusion with host cell membranes. This mechanism is independent of the membrane-lytic activity of other defensin classes.
Bacterial Membrane Disruption
The macrocyclic backbone confers unusual stability against proteolytic degradation. The cyclic structure facilitates insertion into bacterial membranes and maintains antibacterial activity under conditions that would degrade linear peptides. The three disulfide bonds further stabilize the compact folded conformation.
Research Summary
HIV Inhibition
PreclinicalRetrocyclin-1 (RC-1), a synthetic human analog of theta-defensin, inhibits HIV-1 entry into target cells with IC50 values in the low micromolar range. It blocks both CCR5-tropic and CXCR4-tropic strains, suggesting activity against the major circulating viral phenotypes.
Pseudogene Restoration
PreclinicalThe human theta-defensin gene contains a premature stop codon converting it to a pseudogene. Studies using aminoglycosides to suppress this stop codon restored theta-defensin production in human cells. This approach could theoretically restore endogenous antiviral defense in humans.
Calculate your Theta-Defensin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| HIV-1 entry inhibition | 1-10 uM | Single | Cell culture assay |
| Antibacterial MIC | 2-8 mcg/mL | Single | Broth assay |
Research only. No human protocols established for theta-defensins.
Interactions
Safety Profile
Theta-defensins and retrocyclins show favorable selectivity for pathogens over human cells in vitro. The cyclic backbone confers resistance to proteolysis, extending the effective half-life. Systemic administration studies in primates are limited; no clinical data available. Low cytotoxicity to human cells at effective concentrations.
References
- [1]Tang YQ et al. (1999). A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science, 286(5439), 498-502.
- [2]Leikina E et al. (2005). Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nature Immunology, 6(10), 995-1001.